Stephen M. Hahn (born January 22, 1960) is an American physician and radiation oncologist who moved from clinical and academic leadership into national regulatory service. He served as Commissioner of the U.S. Food and Drug Administration (Food and Drug Administration) from December 17, 2019 until January 20, 2021. His time at the agency coincided with the early and most intense phase of the COVID‑19 pandemic in the United States, when regulators faced urgent decisions about diagnostics, therapies and vaccines.

Early career and academic leadership

Hahn trained and practiced as a radiation oncologist and spent much of his career in academic medicine and specialized cancer centers, where he combined patient care, clinical research and executive management. In senior roles he oversaw clinical programs, contributed to clinical-trial design and implementation, and helped integrate new technologies and therapies into practice. These responsibilities prepared him to manage large teams and address regulatory and ethical issues in medicine.

Role at the FDA

As Commissioner, Hahn led an agency responsible for regulation of drugs, biologics, medical devices, foods and combination products. His duties included directing regulatory science priorities, implementing policies for product approval and emergency use, and representing the agency before Congress and the public. He became Commissioner after Senate confirmation late in 2019 and served through a presidential transition in early 2021.

Involvement in the COVID‑19 response

In March 2020 Vice President Mike Pence and Department of Health and Human Services (HHS) Secretary Alex Azar announced Hahn’s addition to the White House Coronavirus Task Force (Coronavirus Task Force), reflecting the FDA's central role in pandemic response. Under his leadership the agency issued and reviewed numerous emergency use authorizations (EUAs) for diagnostics and treatments and later evaluated vaccine EUAs. The urgency of the crisis required balancing accelerated access to medical countermeasures with evolving evidence about safety and effectiveness.

Notable actions and public reception

During Hahn's tenure the FDA took high‑profile actions that drew both praise and criticism. Supporters noted rapid steps to expand testing capacity and to clear products needed for patient care. Some decisions — for example, emergency authorizations issued under time pressure and communications about specific therapies — prompted debate among clinicians and scientists about the adequacy of evidence and the clarity of public messaging. These debates illustrated broader tensions between speed and scientific certainty during a public‑health emergency.

Legacy and perspective

Stephen Hahn's period as FDA Commissioner is frequently discussed in the context of pandemic-era regulatory practice. His career exemplifies a transition from specialty clinical practice and academic administration to national regulatory leadership, underscoring how clinicians and researchers can influence public‑health policy during emergencies. The choices and challenges of that period continue to be examined as part of ongoing lessons about emergency preparedness, regulatory transparency and communication.